#USA #sickle cell disease #Vascarta #VAS-101 #Summit, NJ

Vascarta Initiates Promising Phase I Study of VAS-101 for Sickle Cell Disease

In a significant advancement for treating sickle cell disease (SCD), Vascarta Inc. has announced the commencement of a Phase I clinical trial for its innovative treatment, VAS-101, also known as Vasceptor®. This topical curcumin gel is designed to alleviate pain and reduce complications often associated with SCD, which affects a significant population in the United States and Europe.

Understanding Sickle Cell Disease

Sickle cell disease is an inherited genetic disorder primarily impacting individuals of African American and Hispanic descent. Characterized by a mutation in the beta hemoglobin gene, SCD leads to the sickling of red blood cells, causing severe pain, inflammation, oxidative stress, and organ damage. The condition not only reduces patients' quality of life but also shortens their life expectancy—estimates suggest that individuals with SCD live more than 20 years less than the average lifespan.

For many, pain crises are a pervasive complication that can turn everyday life into a struggle. Current therapies approved by the FDA often do not provide adequate pain relief and come with undesirable side effects, making the need for improved treatment options increasingly urgent.

The Launch of a New Clinical Study

The newly launched Phase I clinical study, titled "A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in Subjects with Stable Sickle Cell Disease," aims to evaluate this new therapy's safety and efficacy. This study, led by Dr. Swee Lay Thein at the NIH Clinical Center, will involve administering varying doses of VAS-101 to participants over a set period.

Patients in the study will apply the topical gel twice weekly, starting at a dose of 0.2 mL, which will gradually increase to 0.4 mL and then 0.6 mL, concluding with follow-up after 14 weeks. Throughout the trial, the team will closely monitor participants for adverse effects and track biomarkers related to the treatment's efficacy.

Potential of VAS-101

VAS-101 is a patented formulation developed by Vascarta, utilizing a unique transdermal delivery technology designed to enhance bioavailability. Previous studies have indicated that curcumin, the active component in VAS-101, can have pain-reducing effects, though its oral absorption has historically been limited.

Dr. Richard Prince, CEO of Vascarta, expressed optimism about this new approach, stating, "Our goal is to provide effective pain management for SCD patients who currently have limited options. If successful, VAS-101 could redefine standards of care."

Moreover, clinical evidence supporting VAS-101 indicates not only safety and tolerability but also potential improvements in pain management and related biomarkers. This could significantly alleviate the need for blood transfusions and decrease reliance on chronic pain medications, paving the way for a new therapeutic standard in SCD treatment.

Addressing an Unmet Medical Need

Dr. Joel Friedman from the Albert Einstein College of Medicine noted the importance of developing therapies that target underlying issues related to SCD. The innovative deployment of curcumin as a topical treatment represents a departure from conventional oral medications, potentially revolutionizing management strategies for patients suffering from this debilitating condition.

As the study progresses, it is hoped that VAS-101 will not only improve pain outcomes but also enhance overall quality of life for SCD patients. The path taken by Vascarta is emblematic of a broader commitment in the medical community to address the significant challenges associated with chronic pain and illness.

This Phase I study marks a vital step forward in the ongoing search for effective, safe treatments for sickle cell disease, ultimately aiming to better the lives of those impacted by this hereditary disorder.